S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden's Plan to Confiscate Your Cash? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden's Plan to Confiscate Your Cash? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden's Plan to Confiscate Your Cash? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Biden's Plan to Confiscate Your Cash? (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
A Hot Tech Company With Strong Patents & Partners (Ad)pixel
NASDAQ:GOSS

Gossamer Bio - GOSS Stock Forecast, Price & News

$13.87
+0.62 (+4.68%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.32
$13.96
50-Day Range
$5.97
$13.87
52-Week Range
$5.64
$14.30
Volume
967,512 shs
Average Volume
1.02 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Gossamer Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
29.8% Upside
$18.00 Price Target
Short Interest
Bearish
26.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.42mentions of Gossamer Bio in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.15 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.64) to ($2.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

407th out of 1,117 stocks

Pharmaceutical Preparations Industry

198th out of 550 stocks

GOSS stock logo

About Gossamer Bio (NASDAQ:GOSS) Stock

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Wall Street Analysts Forecast Growth

GOSS has been the subject of several recent research reports. Piper Sandler reduced their target price on shares of Gossamer Bio from $26.00 to $15.00 in a report on Monday, April 25th. HC Wainwright restated a "buy" rating and set a $20.00 target price on shares of Gossamer Bio in a report on Thursday, July 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Gossamer Bio in a report on Monday, May 9th. Barclays cut their price target on shares of Gossamer Bio from $18.00 to $12.00 and set an "overweight" rating for the company in a research note on Tuesday, April 26th. Finally, Raymond James increased their price target on shares of Gossamer Bio from $10.00 to $14.00 and gave the company an "outperform" rating in a research note on Thursday, July 14th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $18.00.

Gossamer Bio Stock Performance

Shares of GOSS traded up $0.62 during trading hours on Friday, hitting $13.87. The company had a trading volume of 967,512 shares, compared to its average volume of 1,019,957. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -4.36 and a beta of 1.05. The business has a fifty day moving average of $9.34 and a 200-day moving average of $8.85. Gossamer Bio has a 12 month low of $5.64 and a 12 month high of $14.30. The company has a quick ratio of 8.12, a current ratio of 5.24 and a debt-to-equity ratio of 7.44.

Gossamer Bio (NASDAQ:GOSS - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.04). Equities analysts anticipate that Gossamer Bio will post -2.64 EPS for the current fiscal year.

Insider Activity

In related news, CEO Faheem Hasnain acquired 138,696 shares of the company's stock in a transaction dated Friday, July 15th. The shares were bought at an average cost of $7.21 per share, with a total value of $999,998.16. Following the completion of the transaction, the chief executive officer now directly owns 3,617,325 shares of the company's stock, valued at $26,080,913.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other Gossamer Bio news, insider Laura Carter purchased 6,934 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were acquired at an average cost of $7.21 per share, with a total value of $49,994.14. Following the completion of the transaction, the insider now owns 87,168 shares in the company, valued at $628,481.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Faheem Hasnain purchased 138,696 shares of the stock in a transaction that occurred on Friday, July 15th. The shares were acquired at an average cost of $7.21 per share, for a total transaction of $999,998.16. Following the completion of the transaction, the chief executive officer now owns 3,617,325 shares of the company's stock, valued at approximately $26,080,913.25. The disclosure for this purchase can be found here. Insiders have purchased 159,499 shares of company stock valued at $1,149,988 over the last ninety days. 8.30% of the stock is currently owned by company insiders.

Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Stock News Headlines

Analyst Ratings for Gossamer Bio
Where Gossamer Bio Stands With Analysts
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

GOSS Company Calendar

Last Earnings
8/09/2022
Today
8/12/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
185
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+29.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-234,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.18) per share

Miscellaneous

Free Float
70,716,000
Market Cap
$1.07 billion
Optionable
Not Optionable
Beta
1.05

Key Executives

  • Mr. Faheem Hasnain (Age 64)
    Co-Founder, CEO, Pres & Chairman
    Comp: $895.56k
  • Mr. Bryan Giraudo (Age 47)
    COO & CFO
    Comp: $651.8k
  • Mr. Christian Waage (Age 55)
    Exec. VP of Technical Operations & Admin.
    Comp: $583.16k
  • Dr. Laura L. Carter Ph.D. (Age 55)
    Chief Scientific Officer
  • Mr. Jeff Boerneke
    Gen. Counsel & Sec.
  • Ms. Deanna Weber
    Sr. VP of HR
  • Dr. Richard Aranda M.D. (Age 62)
    Chief Medical Officer
  • Mr. Mario Orlando
    Sr. VP of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 63)
    Exec. VP of Regulatory Affairs
  • Mr. Matt Cravets
    Sr. VP of Biometrics













GOSS Stock - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GOSS shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price forecast for 2022?

9 analysts have issued 12-month target prices for Gossamer Bio's shares. Their GOSS share price forecasts range from $12.00 to $24.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2022?

Gossamer Bio's stock was trading at $11.31 at the start of the year. Since then, GOSS shares have increased by 22.7% and is now trading at $13.88.
View the best growth stocks for 2022 here
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) posted its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.04.

What other stocks do shareholders of Gossamer Bio own?

When did Gossamer Bio IPO?

(GOSS) raised $230 million in an initial public offering on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

What is Gossamer Bio's stock symbol?

Gossamer Bio trades on the NASDAQ under the ticker symbol "GOSS."

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Emerald Advisers LLC (2.42%), Walleye Capital LLC (0.72%), Rafferty Asset Management LLC (0.16%), UBS Group AG (0.15%), Swiss National Bank (0.14%) and Rhumbline Advisers (0.10%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Fund V Gp LP Omega, Jakob Dupont, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gossamer Bio's stock price today?

One share of GOSS stock can currently be purchased for approximately $13.88.

How much money does Gossamer Bio make?

Gossamer Bio (NASDAQ:GOSS) has a market capitalization of $1.30 billion. The company earns $-234,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Gossamer Bio have?

The company employs 185 workers across the globe.

How can I contact Gossamer Bio?

Gossamer Bio's mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The official website for the company is www.gossamerbio.com. The company can be reached via phone at (858) 684-1300 or via email at ir@gossamerbio.com.

This page (NASDAQ:GOSS) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.